In randomized trials the use of dual antithrombotic therapy (DAT) versus single antithrombotic therapy (SAT) in patients with chronic coronary syndrome (CCS) reduced the risk of major adverse cardiovascular events [1]. However, the reduction in mortality with DAT was significant only in the COMPASS study and was inconsistent and variable across the other investigations [1]. In particular, what effect on different types of adverse events drives the survival benefit in patients receiving DAT is unclear.
